GLP-1 and AI Search: What 4 Million Conversations From January 2026 Reveal About Your Patients

Let’s be honest about what’s happening here. The patient has changed. Not the biology, not the molecule, not the clinical outcome. The patient’s behaviour. Where they go to learn. What they ask. How long they stay. How they make decisions. And if your content strategy was designed for search engine results pages, you are building for the last channel.

Scrunch AI, a platform that tracks what people actually type into ChatGPT and other AI assistants, analysed millions of real GLP-1 conversations from January 2026. What they found is one of the most useful audience maps I’ve seen in years. Five distinct patient archetypes. Five different jobs to be done. And almost none of them are being served by how pharma brands currently produce content.

I want to walk you through those five archetypes, tell you what each one needs, and give you a clear picture of what a modern digital patient engagement strategy looks like in 2026.

This Isn’t Search Optimization. It’s a Different Medium.

When someone types “Ozempic side effects” into Google, they’re looking for a page. When they type the same question into ChatGPT, they’re starting a conversation. And they come back. That’s the part most marketers miss.

Large language models don’t just answer questions. They build context across a session. A patient who starts by asking “how does Wegovy work” may ask three follow-up questions before they get to “is this covered by my insurance.” They move through awareness, comparison, access, side effects, and adherence support, all inside a single conversation. The funnel isn’t linear. It’s iterative.

In my experience, the brands that win in a channel like this aren’t the ones with the biggest media budget. They’re the ones whose content is structured in a way that AI can actually cite, quote, and recommend. That’s a different problem than SEO. And it requires a different kind of content investment.

Here’s what the Scrunch research tells us about who those patients actually are.

The Five Archetypes. What Each One Actually Needs.

These aren’t demographic segments. They’re behavioural states. The same patient can move between archetypes as their journey evolves. Someone starts as a Knowledge Seeker, becomes an Active Evaluator after their doctor visit, then shifts to a Side Effect Navigator three weeks into treatment. What they need from your content changes at every stage.

The Canadian Context Makes This Even More Urgent

Here’s something that makes Canadian patients particularly active AI searchers: coverage in this country is a mess. Health Canada has approved GLP-1 medications for both diabetes and weight management, but provincial coverage rules are inconsistent. In Ontario, Ozempic is listed as a Limited Use drug. In Alberta, patients often need to try other treatments first. And as of January 2026, no provincial public drug plan covers Wegovy for weight loss.

That coverage complexity feeds directly into the Access Seeker archetype. Canadian patients aren’t just asking “does this work.” They’re asking “can I actually get it, and how much will it cost me.” Telus Health data shows weight-management drug spending has more than quadrupled since 2021, and the category grew 61% in 2025 alone. A generic version of Ozempic is expected in late 2026 at roughly 35% of current list price. That’s going to flood the market with new patients. But it doesn’t mean engagement becomes easier. It means the volume of questions gets higher.

What Patients Are Actually Saying (In Their Own Words)

The Scrunch data gives us the archetypes. Reddit gives us the texture. Here’s what real GLP-1 users are saying in communities like r/Ozempic and r/WegovyWeightLoss, the exact language that then shows up in AI conversations.

That last comment is a strategy brief, not a complaint. If a patient has to go to a general AI assistant to understand how to navigate your product’s access process, you have a content gap that someone will eventually fill.

What a Digital Marketer Should Actually Do With This

For Knowledge Seekers: Be the Source, Not the Result

These patients are building their first mental model of this category. They don’t need a product page. They need a clear, medically accurate explanation of how GLP-1 receptor agonists work, what to expect in the first few weeks, and what questions to ask their doctor. Content that’s structured for AI citation, with clean headers, concise factual statements, and linked sources, gets referenced in AI answers. Generic brand copy doesn’t.

For Active Evaluators: Own the Comparison

These patients will switch based on a single piece of content. They’re comparing efficacy, side effect profiles, cost, and format. If you don’t have a page that addresses those comparisons fairly and clearly, the AI will synthesise one from whatever it can find. And that might include your competitor’s positioning. Active Evaluators also respond to real patient outcomes, the kind that Reddit communities generate organically. You should be connecting to that conversation.

For Access Seekers: Solve the Access Problem in Detail

In Canada, this means province-by-province coverage guidance. It means walking someone through a private insurance appeal. It means explaining the difference between Limited Use criteria in Ontario versus special authorization in Alberta. This kind of content doesn’t get built because it’s not glamorous. But it’s the content that ends up cited in ChatGPT conversations.

For Side Effect Navigators: Retention Is a Content Strategy

Between 20% and 50% of patients stop GLP-1 therapy in the first year. A huge chunk of that discontinuation is driven by side effects that feel scary but are manageable. Side Effect Navigators want reassurance and practical guidance, not clinical disclaimers. Consider tools: an interactive side effect tracker, a symptom checker, a week-by-week guide to what’s normal. These aren’t nice-to-haves. They’re retention strategy.

For Regimen Planners: Build Something Worth Returning To

This archetype has above-median income and a high return rate. They treat AI as a coach. The content opportunity here is a tool, not an article. A meal planning guide that accounts for GLP-1-related appetite changes. An exercise protocol designed for patients on injectable therapies. A CRM journey that mirrors the iterative behaviour Scrunch documented. What I tell my team is: if a Regimen Planner finds your content once and it doesn’t give them a reason to come back, you’ve lost your highest-value patient.

The Real Problem Isn’t Content. It’s Infrastructure.

Here’s the uncomfortable truth for most pharma marketers. The five archetypes above each need different content, different formats, different channel strategies, and different measurement frameworks. But most pharmaceutical marketing organisations are built around campaigns, not customer journeys.

And the AI platforms are changing fast. OpenAI launched ChatGPT Health in January 2026. Anthropic followed with Claude for Healthcare four days later. Both now allow patients to connect their actual health records to AI conversations. The questions AI helps them ask will be far more specific than anything a search engine ever handled.

The brands that win will have built the content infrastructure before that shift fully hits. I’ve seen this firsthand in adjacent categories. The brands that invested in patient education content three years early are the ones that show up authoritatively in AI search today. It’s not luck. Search-optimised content from 2022 is now AI-citation-ready content in 2026. The same principle holds going forward.

The Patient Hasn’t Changed. Their Expectations Have.

GLP-1 patients aren’t more demanding than any other patient population. But they’re operating in a category that moves fast, costs a lot, has real side effects, and has inconsistent access. And they’ve discovered that AI gives them faster, more thorough, more personalised answers than most branded healthcare websites.

That’s not a threat to your brand. It’s an invitation. Build content worth citing. Build tools worth returning to. Build journeys that match the iterative, non-linear way patients actually move through this category.

Four million conversations happened in January. The number will be higher in every month after. The question is how many of those conversations will reference your content, your guidance, your voice. Right now, most of them don’t. That’s the gap worth closing.